Acquiring Company
Sanofi
Acquired Company
Blueprint Medicines
ParisBiotechnologyHealth CareMedicalPharmaceuticalContent And PublishingMedia And EntertainmentHealth CareScience And EngineeringDescription
Sanofi has completed the acquisition of Blueprint Medicines for $9.1 billion in July 2025. Following this acquisition, Sanofi announced plans to lay off 229 workers previously employed at Blueprint Medicines. The layoffs are scheduled to occur between Oct. 9 and late June 2027, as reported in the company's filing with state authorities.
Don't miss Sanofi's next move
Get an email the moment Sanofi makes an acquisition, hires an exec, or expands — usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Blueprint Medicines?
Blueprint Medicines was acquired by Sanofi, based in Paris. The deal was reported on August 17, 2026. Sanofi is publicly traded (SNY) and operates in Biotechnology.
When did Sanofi acquire Blueprint Medicines?
Sanofi's acquisition of Blueprint Medicines was reported on August 17, 2026. Sanofi has completed the acquisition of Blueprint Medicines for $9.1 billion in July 2025. Following this acquisition, Sanofi announced plans to lay off 229 workers previously employed at Blueprint Medicines. The layoffs are scheduled to occur between Oct. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Blueprint Medicines do?
Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. It is privately held, operating in Content And Publishing.